How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,319 results for

Myocardial Infarction Stabilization

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

221. Myocardial Ischemia (Follow-up)

. One study demonstrated a significant reduction of symptomatic myocardial ischemia in patients with unstable angina or non–Q-wave infarction with the administration of a statin during the early acute phase. In a study of 10,001 patients with stable coronary artery disease, an aggressive cholesterol-lowering approach with atorvastatin 80 mg daily (mean cholesterol level of 77 mg/dL) compared to a less-aggressive approach with atorvastatin 10 mg daily (mean cholesterol level of 101 mg/dL) resulted (...) in a 2.2% absolute reduction and a 22% relative reduction in the occurrence of a first major cardiovascular event (defined as death from coronary heart disease; nonfatal, non–procedure-related myocardial infarction; resuscitation from cardiac arrest; or fatal or nonfatal stroke). [ ] This occurred with a greater incidence of elevated aminotransferase levels with the aggressive cholesterol-lowering approach (1.2% vs 0.2%, p < 0.001). Some triglyceride-rich lipoproteins, including partially degraded very

2014 eMedicine.com

222. A comparative study concerning the stability of the anticoagulant effect of acenocoumarol and phenprocoumon. (Abstract)

I6WP63U32H Acenocoumarol AIM IM Acenocoumarol therapeutic use Blood Coagulation drug effects Blood Coagulation Tests Coronary Disease drug therapy Coumarins therapeutic use Female Humans Male Middle Aged Myocardial Infarction prevention & control 1969 10 1 1969 10 1 0 1 1969 10 1 0 0 ppublish 5378105 (...) A comparative study concerning the stability of the anticoagulant effect of acenocoumarol and phenprocoumon. 5378105 1970 05 04 2013 11 21 0001-6101 186 4 1969 Oct Acta medica Scandinavica Acta Med Scand A comparative study concerning the stability of the anticoagulant effect of acenocoumarol and phenprocoumon. 283-8 Breed W P WP van Hooff J P JP Haanen C C eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Sweden Acta Med Scand 0370330 0001-6101 0 Coumarins

1970 Acta Medica Scandinavica Controlled trial quality: uncertain

223. Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.

imaging study was processed and read independently by 3 technologists. Mean heart/mediastinum (H/M) ratio difference (with 95% confidence interval [CI]) was used as the measure of test stability. Secondary Outcome Measures : To Assess the Test-retest Reproducibility of Iobenguane I 123 Injection Myocardial Uptake on Planar Imaging at 15 Minutes Following Administration of AdreView (Iobenguane I 123 Injection) [ Time Frame: 15 minutes post administration of 2 dosing within an interval of 5 to 14 days (...) to enrollment into the study. The participant had received defibrillation either external or via an implantable cardioverter defibrillator (ICD), anti-tachycardia pacing, or cardioversion to treat an arrhythmic event in the previous 90 days. The participant had a cardiac revascularization, insertion of an ICD, or acute myocardial infarction within 30 days before study entry. The participant used any of the following medications: Amitriptyline and derivatives, imipramine and derivatives, other

2013 Clinical Trials

224. Desipramine Pretreatment Improves Sympathetic Remodeling and Ventricular Fibrillation Threshold after Myocardial Ischemia Full Text available with Trip Pro

Desipramine Pretreatment Improves Sympathetic Remodeling and Ventricular Fibrillation Threshold after Myocardial Ischemia Abnormal increase in sympathetic nerve sprouting was responsible for the ventricular arrhythmogenesis after myocardial infarction. This study investigated whether the norepinephrine transporter inhibitor, desipramine, can modulate sympathetic remodeling and ventricular fibrillation threshold (VFT) after myocardial ischemia-reperfusion. Rats were administered desipramine (0.8 (...)  mg/kg, i.v.) before or after myocardial ischemia. VFT, infarct size, tyrosine hydroxylase (TH) and growth-associated protein 43 (GAP43)-positive nerve fibers were measured after one week. The VFT of preischemic treatment group was 11.0 ± 2.65 V and significantly higher than that of control ischemic group (7.2 ± 1.30 V, P < 0.05). Infarct size in the preischemic treatment group (23.3 ± 2.4%) was significantly lower than that in the control ischemic group (30.8 ± 1.3%, P < 0.05) and the delayed

2012 Journal of Biomedicine and Biotechnology

225. Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia

, as documented by echocardiography Planned staged treatment of CAD or other intervention on the heart Platelet count < 100,000/mm3 WBC < 2,000/mm3 TIA or stroke within 90 days prior to randomization ICD shock within 30 days of randomization Any condition requiring immunosuppressive medication A high-risk acute coronary syndrome (ACS) or a myocardial infarction within 60 days prior to randomization Revascularization within 60 days prior to randomization Inability to walk on a treadmill except for class IV (...) Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2012 Clinical Trials

226. Fractional Flow Reserve (FFR) Stability in Non-Culprit Vessels at ST Elevation Myocardial Infarction(STEMI)

Fractional Flow Reserve (FFR) Stability in Non-Culprit Vessels at ST Elevation Myocardial Infarction(STEMI) Fractional Flow Reserve (FFR) Stability in Non-Culprit Vessels at ST Elevation Myocardial Infarction(STEMI) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Fractional Flow Reserve (FFR) Stability in Non-Culprit Vessels at ST Elevation Myocardial Infarction(STEMI) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01065103 Recruitment Status : Completed First Posted : February 9, 2010 Last Update

2010 Clinical Trials

227. Extracorporeal Membrane Oxygenation for Cardiac Indications in Adults

, such as acute myocardial infarction [heart attack] or myocarditis [inflammation of the heart muscle]), valvular dysfunction (damage to any of the four valves that control the flow of blood between the heart’s chambers), or conduction system dysfunction (problems with how electrical impulses travel through the heart and ensure it beats properly). 2 Cardiac arrest and cardiogenic shock are medical emergencies and require immediate treatment. Clinical Need and Target Population Worldwide, the annual incidence (...) to be younger, healthier, and with better prognostic features (characteristics of a patient that can be used to estimate the chance of recovery). Patients who receive timely CPR from bystanders have a greater chance of surviving out-of-hospital cardiac arrest than those who do not. 3 Acute myocardial infarction accounts for about 80% of cardiogenic shock cases. 4 In people with a type of heart attack known as ST-segment elevation myocardial infarction (in which some heart muscle dies due to a block in blood

2020 Health Quality Ontario

229. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic Full Text available with Trip Pro

of this equipment; All patients entering the catheterization laboratory should wear a surgical mask. 5.2.5.1. ST-Segment Elevation Myocardial Infarction Because there is no time to wait for nasopharyngeal swab result, the procedure should be performed in a dedicated catheterization laboratory if available and patients should be triaged according to . In regions with high rates of community transmission, it is reasonable to regard all patients as possible positive and protected accordingly ( ) 5.2.5.2. Non-ST (...) -Segment Elevation Myocardial Infarction – Acute Coronary Syndrome Very high-risk non-ST-segment elevation ( )- should follow the ST-segment elevation myocardial infarction ( ) pathway and protected accordingly; Others should undergo a nasopharyngeal swab immediately after admission ( ). When there are two negative results within 48 hours and absence of suspicious symptoms of virus infection, coronary angiography and eventual percutaneous coronary intervention ( ) may be performed in a catheterization

2020 European Society of Cardiology

230. Preparing for a challenging winter 2020/21

of Medical Sciences 9 2. Health and wellbeing in winter The need for health and social care undergoes large seasonal fluctuations, peaking in the winter. The winter burden on the healthcare system is not only affected by increased incidence of infectious diseases, but also non-infectious conditions that increase in prevalence or are exacerbated during the winter months, such as asthma, chronic obstructive pulmonary disease (COPD), ischaemic heart disease, myocardial infarction and stroke. Every winter

2020 Academy of Medical Sciences

231. 2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease

coronary syndromes AED Automatic external defibrillator AHA American Heart Association AF Atrial fibrillation AFL Atrial flutter AMI Acute myocardial infarction AN-SUD Autopsy-negative sudden unexplained death AP Accessory pathway AOCA Anomalous origin of coronary arteries AR Aortic valve regurgitation ARVC Arrhythmogenic right ventricular cardiomyopathy AS Aortic valve stenosis ASI Aortic size index AVNRT Atrioventricular nodal re-entrant tachycardia AVRT Atrioventricular re-entrant tachycardia BAV (...) LBBB Left bundle branch block LDL Low-density lipoprotein LEAD Lower extremity artery disease LGE Late gadolinium enhancement LV Left ventricular LVEDD Left ventricular end-diastolic diameter LVEF Left ventricular ejection fraction LVNC Left ventricular non-compaction LVOT Left ventricular outflow tract LQTS Long QT syndrome MACE Major adverse cardiovascular events MB Myocardial bridge/bridging MCE Moderate continuous exercise MET Metabolic equivalent MFS Marfan syndrome MI Myocardial infarction MR

2020 European Society of Cardiology

232. 2020 Atrial Fibrillation (Management of) Guidelines

Fibrillation-Thrombolysis In Myocardial Infarction 48 ENTRUST- AF PCI Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention ESC European Society of Cardiology GARFIELD-AF Global Anticoagulant Registry in the FIELD − Atrial Fibrillation GDF-15 Growth differentiation factor-15 HAS-BLED Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly (>65 years), Drugs/alcohol concomitantly (...) -segment elevation myocardial infarction TIA Transient ischaemic attack TOE Transoesophageal echocardiography TTR Time in therapeutic range UFH Unfractionated heparin US United States of America VHD Valvular heart disease VKA Vitamin K antagonist WOEST What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing 1 Preamble Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best

2020 European Society of Cardiology

233. 2020 Acute Coronary Syndromes (ACS) in Patients Presenting without Persistent ST-Segment Elevation (Management of) Guidelines Full Text available with Trip Pro

, Select Format Download citation Navbar Search Filter Mobile Microsite Search Term search filter search input , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , For the which include background information and detailed discussion of the data that have provided the basis for the Guidelines see online. Table of contents Abbreviations and acronyms 5 1 Preamble 7 2 Introduction 8 2.1 Definitions 8 2.1.1 Universal definition of myocardial infarction 8 2.1.1.1 Type 1 (...) myocardial infarction 8 2.1.1.2 Type 2 myocardial infarction 9 2.1.1.3 Types 3–5 myocardial infarction 9 2.1.2 Unstable angina in the era of high-sensitivity cardiac troponin assays 9 2.2 Epidemiology 9 2.3 What is new? 9 2.4 Number and breakdown of classes of recommendations (Supplementary Data) 10 3 Diagnosis 10 3.1 Clinical presentation (Supplementary Data) 10 3.2 Physical examination (Supplementary Data) 10 3.3 Diagnostic tools 10 3.3.1 Electrocardiogram 10 3.3.2 Biomarkers: high-sensitivity cardiac

2020 European Society of Cardiology

234. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Full Text available with Trip Pro

Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. To investigate growth differentiation factor (GDF)-15 at hospital discharge for assessment of the risk of death, recurrent myocardial infarction (MI), and congestive heart failure, and to determination of whether these risks can be modified by statins.GDF-15 is a transforming growth factor-β-related cytokine induced in response to tissue injury

2011 Arteriosclerosis, thrombosis, and vascular biology Controlled trial quality: uncertain

235. HFR A-equilibrium on Cardiovascular Stability

less than 2 ml/min/1.73 m2 native fistula or central venous catheter with blood flow rate greater than 250 ml/min Exclusion Criteria: Life expectancy less than 1 year solid active neoplasm pregnancy major event in the previous 3 months (ictus, myocardial infarction, cachexia) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor (...) HFR A-equilibrium on Cardiovascular Stability HFR A-equilibrium on Cardiovascular Stability - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. HFR A-equilibrium on Cardiovascular Stability (AIMS) The safety

2011 Clinical Trials

236. A randomised study of perioperative esmolol infusion for haemodynamic stability during major vascular surgery; rationale and design of DECREASE-XIII. Full Text available with Trip Pro

of heart rate outside the target window during infusion of the study drug. Secondary outcome measures will be the efficacy parameters of occurrence of cardiac ischaemia, troponin T release, myocardial infarction and cardiac death within 30 days after surgery and safety parameters such as the occurrence of stroke and hypotension.This study will provide data on the efficacy of esmolol titration in chronic beta-blocker users for tight heart-rate control and reduction of ischaemia in patients undergoing (...) A randomised study of perioperative esmolol infusion for haemodynamic stability during major vascular surgery; rationale and design of DECREASE-XIII. This article describes the rationale and design of the DECREASE-XIII trial, which aims to evaluate the potential of esmolol infusion, an ultra-short-acting beta-blocker, during surgery as an add-on to chronic low-dose beta-blocker therapy to maintain perioperative haemodynamic stability during major vascular surgery.A double-blind, placebo

2011 European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery Controlled trial quality: predicted high

237. Polyvalent immunoglobulins – Part 1: A rapid review

with a focus on AEs from general search The SR by Ammann et al. (AMSTAR 8/11), focused on thromboembolic events (TEEs). The SR focused only on RCTs with a low RoB, and included 31 studies overall, on 4129 patients 37 . The median length of follow-up was 9 months and the median of the trial mean ages was 47 years (ranging from 29 to 70 years). The main outcome of interest was the rate of serious TEEs (i.e. acute myocardial infarction; ischemic stroke or venous thromboembolism). Arterial and venous TEEs were (...) LoS Length of Stay MA Meta-Analysis MFAs Myocardial Function Abnormalities MG Myasthenia Gravis MM Multiple Myeloma MMN Multifocal motor neuropathy MMRC Modified Medical Research Council MORSE report Monitoring Of Reimbursement Significant Expenses - report NBA National Blood Authority (Australia) NHS England National Health Service England NIHDI-RIZIV-INAMI PE National Institute of Health and Disability Insurance Plasma Exchange PID PP Primary Immunodeficiency Per protocol PTP Post transfusion

2020 Belgian Health Care Knowledge Centre

239. Canadian guidelines on opioid use disorder among older adults

are detrimental, including nausea and vomiting, constipation, sedation, mood changes, myocardial infarction, immunosuppression, and trauma, the latter of which includes falls, fractures, and motor vehicle accidents . Other harmful effects of opioids include hormone suppression leading to sexual dysfunction and osteoporosis, dry mouth leading to tooth decay, respiratory depression leading to sleep apnea and/or overdose (sometimes fatal), and addiction (Baldini et al ., 2012) . Most clinicians are aware (...) patient as an individual . Tapering opioids in older adults with pain (and without an OUD) may offer the advantage of increased cognitive alertness and lower the risk of potential adverse outcomes (e .g ., falls, myocardial infarction, sleep apnea, overdose,) . However, tapering opioids can also pose some risks if done inappropriately . Too great or too frequent a dose drop or abrupt cessation can lead to overwhelming withdrawal symptoms including pain, anxiety, insomnia, lowering of mood (including

2019 CPG Infobase

240. Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis Full Text available with Trip Pro

. Fontana M. Gilbertson J.A. et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging. 2016; 9 ( e005066 ) Amyloid deposits around coronary microvasculature can lead to angina or rarely myocardial infarction in the absence of epicardial coronary artery disease. shows a summary of important cardiovascular manifestations of cardiac amyloidosis. Figure 1 Cardiovascular (...) -photon emission computed tomography can also help differentiate the regional myocardial uptake seen in patients with a history of myocardial infarction from the diffuse myocardial uptake typical of ATTR, improving diagnostic accuracy in this setting. Dorbala S. Ando Y. Bokhari S. et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019; 26 : 2065

2020 Canadian Cardiovascular Society

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>